Clinical Trials Logo
  1. Home
  2. Hematologic Diseases
  3. NCT01108159
  4. Details
NCT01108159 Clinical Trial

Integrated Whole-Genome Analysis of Hematologic Disorders

Hematologic Diseases Clinical Trial

Official title:
Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01108159
Other study ID # HEM0013
Secondary ID 1081737-100-DHAA
Status Completed
Phase
First received
Last updated
Start date September 2009
Est. completion date August 2, 2013

Study information
Verified date May 2018
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.

Recruitment information / eligibility
Status Completed
Enrollment 35
Est. completion date August 2, 2013
Est. primary completion date August 2, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. 18 years of age or older

2. Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.

3. Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

1. Less than 18 years of age

2. Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Blood Draw

• Skin Biopsy

Locations
Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)
Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression sample collection at time of routine visit
See also
  Status Clinical Trial Phase
Recruiting NCT04094844 - Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation N/A
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT03918343 - Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation N/A
Completed NCT01445561 - Ultra Low Dose Interleukin-2 in Healthy Volunteers Phase 1
Recruiting NCT06148610 - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Completed NCT04168983 - Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy N/A
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Completed NCT00800839 - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide Phase 2
Completed NCT00213239 - A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children Phase 1/Phase 2
Terminated NCT00208949 - A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF Phase 2
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Completed NCT00208962 - Allogeneic Cell Therapy for Adults With Hematologic Malignancies Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Recruiting NCT05487794 - Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis N/A
Completed NCT03611257 - Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases N/A
Completed NCT02827149 - High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
Completed NCT04584528 - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease N/A